

A second-generation medicines access collaboration: CMLPath to Care™

Novartis and The Max Foundation are collaborating on a new, independent, patient-centered access model for people living with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers in lower-income countries called CMLPath to Care™.



CMLPath to Care is an evolution from a previous patient access program, which since 2002 provided medication at no cost to properly diagnosed patients in lower-income countries without access to reimbursement or funding mechanisms and to patients unable to pay for the medication. Since its inception, the collaboration has reached 75,000 total patients. About 90% of patients enrolled receive treatment for CML. The remaining are treated for GIST or other rare cancers.

CMLPath to Care is one of the broadest cancer access initiatives led by a patient-centered non-governmental organization (NGO), with treatment and support provided at no cost to individual patients. This model contrasts with more traditional programs that provide bulk donations of a medicine.

Over the next four years

NOVARTIS WILL DONATE

More than

\$29 million

to the collaboration

along with approximately

315 million

doses of medicine

1 Novartis donates medicine and funding to the Max Foundation

2 The Max Foundation delivers medicine to health centers and institutions in nearly 70 countries

3 Physicians provide medicine to individual eligible patients

4 The Max Foundation also provides continued psycho-social support and education through local advocacy organizations

Reimagining what is possible



The partnership with the Max Foundation has been a key component of the Company's long-term focus on bringing CML care to those who need the most support. Novartis holds an unwavering commitment to reimagining what is possible for CML treatment through scientific innovations and creative solutions that provide access to care regardless of geography or financial situation.

As a leader in CML for more than 15 years, Novartis believes in equitable access to care, so regardless of geography or financial situation people can receive the medications and support needed to manage their CML.

CMLPath to Care around the globe



More than
34,000
CURRENT PATIENTS

1,400
TRAINED
PHYSICIANS

450
TREATMENT
CENTERS

Nearly
70  **4**
COUNTRIES CONTINENTS

 Approximately
75,000
TOTAL PATIENTS ASSISTED
since 2002

As of June 2017